【Asset for Licensing】Novel STEAP1/PSMA/CD3 trispecific antibody for Prostate Cancer

Asset: Novel STEAP1/PSMA/CD3 trispecific antibody
Development Stage: IND enabling stage
Indication: Prostate Cancer
Key Asset Highlights:
（1）Features a unique trispecific antibody design targeting STEAP1, PSMA and CD3, integrating dual tumor antigen recognition and T-cell redirection functions to achieve precise and robust tumor immunotherapy.
（2）Enables dual-antigen-dependent T-cell activation and tumor cell killing, significantly reducing off-tumor toxicity and lowering the risk of antigen loss-mediated drug resistance compared with conventional single-target bispecific antibodies.
（3）Effectively recruits and activates endogenous CD3-positive T cells within the tumor microenvironment, triggering potent and sustained anti-tumor immune responses against PSMA/STEAP1-positive prostate cancer cells.
（4）Demonstrates superior and differentiated preclinical anti-tumor efficacy for both early-stage and refractory prostate cancer, providing an innovative immune therapeutic option for intractable disease with unmet clinical needs.
（5）Possesses optimized molecular structure and favorable developability profiles with stable biochemical properties, supporting subsequent process development and clinical transformation.
（6）Backed by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for prostate cancer immunotherapy.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.